Zevra Therapeutics (NASDAQ:ZVRA) Insider Joshua Schafer Sells 3,375 Shares

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) insider Joshua Schafer sold 3,375 shares of the business’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $8.83, for a total transaction of $29,801.25. Following the completion of the sale, the insider directly owned 37,444 shares of the company’s stock, valued at approximately $330,630.52. This trade represents a 8.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Zevra Therapeutics Stock Performance

Shares of ZVRA traded up $0.36 during midday trading on Monday, reaching $9.36. 1,074,144 shares of the stock were exchanged, compared to its average volume of 1,039,668. The business’s 50-day moving average price is $8.64 and its 200 day moving average price is $9.45. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.62 and a quick ratio of 8.57. Zevra Therapeutics, Inc. has a twelve month low of $6.19 and a twelve month high of $13.16. The company has a market capitalization of $526.97 million, a price-to-earnings ratio of 19.91 and a beta of 0.99.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.03. The company had revenue of $26.06 million for the quarter, compared to analyst estimates of $26.64 million. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%. On average, sell-side analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ZVRA. Ameritas Investment Partners Inc. boosted its position in shares of Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after purchasing an additional 1,280 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Zevra Therapeutics by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock valued at $179,000 after purchasing an additional 1,750 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Zevra Therapeutics by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after purchasing an additional 1,812 shares during the period. CWM LLC boosted its holdings in Zevra Therapeutics by 399.5% during the third quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after buying an additional 2,297 shares in the last quarter. Finally, Carret Asset Management LLC boosted its holdings in Zevra Therapeutics by 9.7% during the second quarter. Carret Asset Management LLC now owns 39,640 shares of the company’s stock worth $349,000 after buying an additional 3,500 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Cantor Fitzgerald dropped their price objective on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. HC Wainwright set a $26.00 price target on Zevra Therapeutics in a research report on Tuesday, December 30th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Canaccord Genuity Group lowered their target price on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Zevra Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $22.80.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.